CalciMedica, Inc. (CALC) — Stock Valuation & Research

CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute…

CALC key statistics

Explore CALC's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.